Ropes & Gray Represents Verastem Oncology in Mirati Therapeutics Collaboration for Non-Small Cell Lung Cancer
Ropes & Gray advised Verastem Oncology in a collaboration to evaluate Mirati Therapeutics’ investigational KRAS inhibitor drug with Verastem’s investigational inhibitor drug in combination for mutant non-small cell lung cancer. The transaction was announced on November 22.
The Ropes & Gray team was led by life sciences partner Abigail Gregor and life sciences associate Amanda White (both of Boston).